Showing 851-860 of 936 results for "".
- Flavonoid-Rich Diet May Increase Life Expectancy in Parkinson Diseasehttps://practicalneurology.com/news/flavonoid-rich-diet-may-increase-life-expectancy-in-parkinson-disease/2469806/A study published in Neurology, showed a diet that includes 3 or more servings per week of high-flavonoid foods may lower chance of dying in individuals with Parkinson disease (PD) compared with those who
- Ketogenic Diet Results in Metabolic Changes in Astrocytomahttps://practicalneurology.com/news/ketogenic-diet-cause-metabolism-changes-in-treated-individuals-with-astrocytomas/2469634/According to a new study published in Neurology, a ketogenic diet may be beneficial for individuals with astrocytomas. Brain scans of 21 of 25 participants who completed the study and followed the di
- Plant-Based Diet Correlates With Reduced Stroke Riskhttps://practicalneurology.com/news/plant-based-diet-correlates-with-reduced-stroke-risk/2469525/A study published in Neurology, showed a correlation between a diet high in quality plant-based foods and up to a 10% reduced risk of ischemic. Compared with people who ate the fewest healthful plant-based foods, people who ate the most had a 10% lower risk of having a stroke. Participa
- Healthy Diet May Reduce Nonmotor Symptoms of Prodromal Parkinson Diseasehttps://practicalneurology.com/news/healthy-diet-may-reduce-nonmotor-symptoms-of-prodromal-parkinson-disease/2469355/A new study published in the August 19, 2020 online issue of Neurology suggests that eating a healthy diet in midlife may be linked to fewer nonmotor symptoms of Parkinson Disease (PD). In this study, participants who strictly followed specific healthy diets were less likely to ha
- Diet High in Fish and Vegetables May Help Preserve Cognitionhttps://practicalneurology.com/news/diet-high-in-fish-and-vegetables-may-help-preserve-cognition/2469228/Results of a study published in Alzheimer (AD) and Dementia show adherence to the Mediterranean diet (high in vegetables, whole grains, fish, and olive oil) correlates with higher cognitive function. Dietary factors also seem to play a role in slowing cognitive decline. Researchers at the Nationa
- Antibody–Oligonucleotide Conjugate Shows Target Engagement in Myotonic Dystrophy Type 1https://practicalneurology.com/news/antibodyoligonucleotide-conjugate-shows-target-engagement-in-myotonic-dystrophy-type/2485921/Treatment with delpacibart etedesiran (del-desiran [AOC 1001]; Avidity Biosciences, San Diego, CA), a monoclonal antibody (mAb) oligonucleotide conjugate, reduced DMPK mRNA levels and demonstrated improvement in downstream splicing biomarkers in adults with myotonic dystrophy type 1 (DM1). These
- FDA Grants Breakthrough Therapy Designation to Delpacibart Zotadirsen for Duchenne Muscular Dystrophyhttps://practicalneurology.com/news/fda-grants-breakthrough-therapy-designation-to-delpacibart-zotadirsen-for-duchenne-muscular-dystrophy/2475932/Del-zota (delpacibart zotadirsen; Avidity Biosciences, San Diego, CA) has been granted Breakthrough Therapy designation by the Food and Drug Administration (FDA) as an investigational therapy for the treatment of people with Duchenne muscular dystrophy (DMD) with mutations amenable to exon 44 ski
- Draft Guidelines for the Treatment of Infantile Epilepsy Syndromes: Comments Requestedhttps://practicalneurology.com/news/new-guidelines-proposed-for-treatment-of-infantile-epilepsy-syndromes-comments-requested/2475300/The American Epilepsy Society (AES) has released a comprehensive draft clinical practice guideline that provides evidence-based recommendations for the pharmacologic, surgical, and dietary treatment of epilepsy syndromes in infants aged <36 months. The guideline updates a previously published
- Ingrezza Treatment for Older Adults with Tardive Dyskinesia Safe and Effective Long-Term According to New Studyhttps://practicalneurology.com/news/ingrezza-treatment-for-older-adults-with-tardive-dyskinesia-demonstrates-long-term-safety-and-efficacy/2474394/According to results of a post hoc analysis of the KINECT-3 (NCT02274558) and KINECT-4 (NCT02405091) clinical studies published in the Journal of Clinical Psychiatry, older adults with tardive dyskinesia (TD) treated with once-daily Ingrezza (valbenazine; Neurocrine Biosciences, San Dieg
- Ingrezza Treatment for Tardive Dyskinesia Improved Functional, Social, Emotional, and Health-Related Quality of Life Measureshttps://practicalneurology.com/news/ingrezza-treatment-for-tardive-dyskinesia-improved-functional-social-emotional-and-health-related-quality-of-life-measures/2470633/Treatment with Ingrezza (valbenazine; Neurocrine Biosciences, San Diego, CA) was associated with improvements in functional, social, emotional, and health-related quality of life measures for people with tardive dyskinesia (TD). The findings of 3 separate analyses of clinical study and survey dat